Overview

     

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter
What is this?

EnteroMedics Inc. (NASDAQ: ETRM)			4:00 PM ET on May 22, 2013
Last Price	Change	Open	Day High	52-Week High
1.04	0.03    (2.804%)	1.06	1.16	4.40
	Volume	Previous Close	Day Low	52-Week Low
	1,648,700	1.07	1.02	0.81

View all »Recent Releases

May 22, 2013
EnteroMedics to Participate in the Craig-Hallum Annual Institutional Investor Conference

May 17, 2013
EnteroMedics Completes VBLOC Therapy Pre-PMA Meeting With FDA

This website contains forward-looking statements about EnteroMedics^® Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our lack of commercial regulatory approval for our Maestro® System for the treatment of obesity in the United States or in any foreign market other than the European Community and Australia; our preliminary findings from our EMPOWER™ pivotal trial; our ability to comply with the Nasdaq continued listing requirements; our ability to commercialize our Maestro System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our Maestro System; physician adoption of our Maestro System and VBLOC® vagal blocking therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission, particularly those factors identified as “risk factors” in the current report 8-K filed with the Securities and Exchange Commission on September 28, 2011. We are providing this information as of the date of this presentation and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.